Stock Ratings / Health Care / AMGN / earnings

GILD (82) MRNA (60) ARGX (63) RVMD (55) ⌘ Pro Terminal →

Amgen Inc. (AMGN) Next Earnings Date & Expected ±5.2% Move

$466.01 +1.15% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $468.09

Amgen Inc. (AMGN) earns a Roarable Rating of B- (Buy) with 71/100 RQD Confidence. High-quality cash engine (67% profit margin, 15% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

📊 Historical Track Record: Scores of 71/100 (B-) historically ranked in the Top 14% of excess returns over the next 90 days (+6.8% avg 90D alpha vs SPY • 68.4% hit rate) →

ROARABLE B- • BUY Cap $249.09B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on AMGN Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is AMGN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Amgen Inc. (NASDAQ: AMGN) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 71/100 at a spot price of $466.01 (+1.15% 1D, market cap $249.09B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 19/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, AMGN ranks #74 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does AMGN compare to GILD and MRNA in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), AMGN carries a Roarable B- (71/100 RQD), trailing P/E of 32.3x, gross margin of 67.2%, and ROIC of 14.5%. By comparison, GILD (Gilead Sciences Inc.) holds a A- grade (82/100 RQD, P/E 24.1x, ROIC 21.0%, cap $205.35B) and MRNA (Moderna Inc.) posts a C- grade (60/100 RQD, P/E N/A, ROIC -34.1%, cap $88.93B). Among the 5-stock peer group, GILD leads on earnings multiple (24.1x) while GILD leads on capital efficiency (21.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for AMGN?

▼

Per AMGN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000318154), Amgen Inc. generated $36.75B in revenue (+10.0% YoY), $7.71B in net income, and $8.10B in free cash flow against $90.59B in total assets and $50.01B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $468.11 (+0.45%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 13/20 (C) • 22% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 71/100 (B-) historically ranked in the Top 14% of excess returns over the next 90 days (+6.8% avg 90D alpha vs SPY • 68.4% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERBUY • B-

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B+ · Rk C-

Each axis scored 0–20

12M PRICE TARGET CONE+5.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AMGN)Realized 20D OHLCV Swing Band: ±5.2%

Deterministic 5-Pillar Attribution (71/100 Composite)

🔍 WHY AMGN SCORES 71/100 (B-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+19/20 pts (27% of score)

20D Institutional Volume Accumulation (±5.2% realized swing band)

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+15/20 pts (21% of score)

SEC Form 4 / 13F Thermometer: 75% Net Buy • Cannibal Buyback (-2.08% YoY Shares)

▼ #1 Drag / Risk Factor: Macro Regime Fit10/20 pts (-10 pt drag)

Macro rate sensitivity & RSI-14 (67) create a -10 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C+$412.84+6.3% Next Q

Q2 (-2Q)

Grade B-$438.94+2.1% Next Q

Q3 (-1Q)

Grade B-$447.95+4% Next Q

Current

Grade B-$466.01+6.8% Hist 90D α

Trajectory: C+ (63) → B- (71)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the AMGN Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 71/100 (B-) score, AMGN faces multiple-compression risk if 32.3x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 64.7% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($420.73) or 200D SMA ($376.09) invalidates the momentum regime and cuts Target Base ($493.27) toward Bear Floor ($382.13).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $AMGN• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “AMGN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 71%NO 29%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 30, 2026 (~57 DAYS)

Historical OHLCV Volatility ±5.2% Swing Band

±$24.23 Expected Swing

MODEL EARNINGS SETUP GAUGE

AMGN Quantitative Pre-Earnings Setup: 71/100

Trailing EPS: $14.26 • YoY Revenue Growth: 10%

Model Bullish Setup (71/100)Model Risk Weight (29/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$36.75B	$7.71B	$8.10B	67.2%
FY 2024	2024-12-31	$33.42B	$4.09B	$10.39B	61.5%
FY 2023	2023-12-31	$28.19B	$6.72B	$7.20B	67.2%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating AMGN & AI Leaders Without Chasing Tops

✓Institutional whale strikes & implied earnings move audit on AMGN
✓How disciplined traders manage risk using pre-published trigger & invalidation levels
✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

AMGN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +43.90%⚡ TESTING RESISTANCE

2026-11-02O $451.8H $466.0L $451.8C $466.0VOL 2.98M

RES: $476.9SUP: $398.8SMA50: $420.7SMA200: $376.1

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AMGN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 AMGN Butterfly Map → + Track AMGN →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

25.0%/yr Implied 5Y Growth

vs. +10.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on AMGN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for AMGN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for AMGN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AMGN)

Health Care Rank #74 of 1016 ⚔️ GILD vs AMGN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (AMGN vs. GILD, MRNA, ARGX, RVMD)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Amgen Inc. (AMGN) ranks #74 by composite RQD confidence (71/100, grade B-) and #9 by equity capitalization ($249.09B). Within this direct 5-issuer industry benchmark cohort, GILD leads on earnings valuation at 24.1x trailing P/E, while GILD leads on capital efficiency and profitability with 21.0% ROIC and 78.8% gross margin. GILD currently holds the highest overall quantitative score in the immediate peer group at 82/100 (A-) compared with AMGN at 71/100 (B-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
AMGN ACTIVE Amgen Inc.	B-	71/100	32.3x	67.2%	14.5%	+1.15%	$249.09B	Benchmark Subject
GILD Gilead Sciences Inc.	A-	82/100	24.1x	78.8%	21.0%	+3.06%	$205.35B	/gild-vs-amgn →
MRNA Moderna Inc.	C-	60/100	—	55.3%	-34.1%	-0.47%	$88.93B	/mrna-vs-amgn →
ARGX argenx SE	C	63/100	32.8x	—	9.9%	-0.56%	$55.72B	/argx-vs-amgn →
RVMD Revolution Medicines Inc.	D+	55/100	—	—	-28.6%	+0.55%	$40.78B	/rvmd-vs-amgn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000318154

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Amgen Inc. (AMGN) reported GAAP revenue of $36.75B (+10.0% vs. FY2024 revenue of $33.42B , and +30.4% cumulative change since FY2023) , GAAP net income of $7.71B, operating cash flow of $9.96B, and free cash flow of $8.10B (-22.1% YoY). On the balance sheet, AMGN closed FY2025 with $90.59B in total assets against $50.01B in total debt (Altman Z-Score: 3.83, Piotroski F-Score: 8/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$36.75B	$7.71B	$9.96B	$8.10B	$90.59B	$50.01B
FY2024 (FY)	2024-12-31	$33.42B	$4.09B	$11.49B	$10.39B	$91.84B	$56.55B
FY2023 (FY)	2023-12-31	$28.19B	$6.72B	$8.47B	$7.20B	$137.00B	$32.06B

3. AMGN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AMGN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does AMGN compare to GILD and MRNA in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for AMGN?

Where is AMGN trading relative to its 50-day, 200-day, and 52-week technical levels?

AMGN last traded at $466.01 (+1.15% on volume of 3,290,628 shares), positioning the stock +10.76% above its 50-day simple moving average ($420.73) and +23.91% above its 200-day simple moving average ($376.09). Across its 52-week range of $292.12 to $475.65, AMGN sits at the 94.7% percentile with a 14-day RSI of 67.0 (BULLISH MOMENTUM) and an implied next-earnings move of ±5.2% ($441.78 to $490.24).

AMGN Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is AMGN's next earnings date?

Based on SEC filing cadence, Amgen Inc. (AMGN)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is AMGN stock expected to move on earnings?

Volatility modeling currently projects a ±5.2% event move for AMGN, spanning a range between $441.78 and $490.24.

Direct Sub-Reports: AMGN RQD Cockpit AMGN 12M Forecast AMGN Earnings & Move AMGN Dividends & DRIP AMGN Insiders & 13F AMGN Whale Options AMGN Profit Sankey AMGN News & Why

Sector Peer Dials

Revolution Medicines Inc.

AMGN Core Snapshot

Market Cap $249.09B

Trailing / Fwd P/E 32.3x / 30.0x

Gross Profit Margin 67.2%

Return on Capital (ROIC) 14.5%

Free Cash Flow Yield 3.25%

12M Base Price Target $493.27

FREE TRADER TOOLS

Own AMGN Alongside Other Stocks? Run a 30-Second Crash X-Ray

Drop 3–5 tickers into our live Portfolio X-Ray to spot hidden accounting time-bombs and see your composite RQD dial.

⚡ X-Ray My Portfolio With AMGN → 🏆 Trade AMGN in $100K Prop Arena →

AMGN Wire

Why It Moved →

Direct Company Event Yahoo Finance • 7h ago

Amgen (AMGN) Laps the Stock Market: Here's Why

Peer / Ecosystem Wire Trefis • 10h ago

What Would It Take For Amgen Stock To Move Higher?

Direct Company Event TradingKey • 13h ago

Amgen Stock Forecast: Sjögren’s Trial Success Tests AMGN’s Pipeline Outlook

Direct Company Event Yahoo Finance • 16h ago

Amgen (AMGN) Stock Could Be 40% Undervalued On KRAS Market Growth News

Direct Company Event TradingKey • 19h ago

Amgen Inc Stock (AMGN) Moved Up by 3.29% on Oct 14: Key Drivers Unveiled

ROARABLE RATING BRIEF • RQD 71/100 (B-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

AMGN — Amgen Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:08:58Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, AMGN scores 71 out of 100, graded B-, with the verdict "Roarable Buy — Sound Institutional Accumulation." The five pillars are:

Fundamental Cash Engine (13 / 20): Per the RQD rating, this pillar reflects ROIC of 14.5% and an FCF yield of 3.25%. Investor implication: returns on capital are respectable, but the free-cash-flow yield is modest relative to a roughly $249.09B market cap and a 32.3x trailing P/E, so cash generation alone does not justify the valuation; investors are paying for expected future growth.
Whale 13F Flow (19 / 20): Per the RQD rating, this is the strongest pillar, indicating institutional accumulation and options positioning. Investor implication: sophisticated holders appear to be building positions, which is a supportive signal, though it does not guarantee future price performance.
Insider Conviction (15 / 20): Per the RQD rating, SEC Form 4 and Congressional PTR cluster flow is scored as moderately positive. Investor implication: insider activity provides some confidence signal but is not a standalone buy trigger.
Macro Regime Fit (10 / 20): Per the RQD rating, beta of 0.87 and sector sensitivity produce a below-midpoint score. Investor implication: the stock is less volatile than the broad market (beta below 1.0), which can cushion drawdowns, but the score signals limited tailwind from the current macro regime.
Forensic Balance Sheet (14 / 20): Per the RQD rating, Altman Z of 3.83, Piotroski F of 8/9, and Debt/Equity of 5.78 combine into a solid but leveraged profile. Investor implication: the Z-score and F-score point to financial health and improving fundamentals, while the high Debt/Equity ratio is a key tradeoff to monitor if rates or refinancing conditions tighten.

Taken together, the 71 score reflects strong institutional interest and a healthy balance-sheet profile, offset by a rich valuation (32.3x P/E TTM, 27.2x EV/EBITDA) and a limited macro tailwind. The valuation tradeoff is the central consideration for a prospective investor.

Snapshot

Price	Market Cap	P/E (TTM)	Forward P/E	EV/EBITDA	EPS (TTM)	Dividend Yield	Beta	52-Wk Range	ROIC %
$460.73	$249.09B	32.3	30	27.2	14.26	2.06%	0.87	$292.12 - $475.65	14.5%

Recent Catalysts & News Wire Analysis

Per the news wire, Yahoo Finance reported on AMGN's market action and institutional positioning (flagged YELLOW, market wire).
Per the news wire, Trefis discussed what would drive the stock higher (flagged YELLOW).
Per the news wire, TradingKey covered a Sjögren's trial success and its implications for the pipeline outlook (flagged YELLOW).
Per the news wire, a Yahoo Finance report discussed a possible KRAS market growth opportunity, framed as a potential undervaluation (flagged GREEN, catalyst).
Per the news wire, TradingKey reported a 3.29% move on Oct 14 with key drivers (flagged YELLOW).
Per the news wire, Yahoo Finance profiled AMGN as a trending stock (flagged YELLOW).

Risk watch items: the source data does not specify the magnitude of trial outcomes or the timeline of pipeline catalysts. Per the butterfly graph, proprietary signals are none.

Open Questions

What are the specific products and revenue mix driving the FY 2025 revenue of $36751.0M, and how concentrated is it?
What is the reported EPS for each period, given that the financials list EPS as N/A?
What are the timelines, probabilities, and commercial potential of the Sjögren's and KRAS programs referenced in the news?
How is the $50005.0M debt structured (maturities, rates, covenants), and what drives the 5.78 Debt/Equity ratio?
What are the upstream and downstream dependencies and any analyst price targets?

AMGN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Amgen Inc. (AMGN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to AMGN Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 7h ago

Amgen (AMGN) Laps the Stock Market: Here's Why

Yahoo Finance report covering Amgen Inc. (AMGN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Trefis • 10h ago

What Would It Take For Amgen Stock To Move Higher?

Trefis report covering Amgen Inc. (AMGN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingKey • 13h ago

Amgen Stock Forecast: Sjögren’s Trial Success Tests AMGN’s Pipeline Outlook

TradingKey report covering Amgen Inc. (AMGN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 16h ago

Amgen (AMGN) Stock Could Be 40% Undervalued On KRAS Market Growth News

Yahoo Finance report covering Amgen Inc. (AMGN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingKey • 19h ago

Amgen Inc Stock (AMGN) Moved Up by 3.29% on Oct 14: Key Drivers Unveiled

TradingKey report covering Amgen Inc. (AMGN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 22h ago

Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It

Yahoo Finance report covering Amgen Inc. (AMGN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Amgen (AMGN) and Johnson & Johnson (JNJ) Catch Jim Cramer’s Eye for Different Reasons

Yahoo Finance report covering Amgen Inc. (AMGN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Amgen (AMGN) Advances While Market Declines: Some Information for Investors

Yahoo Finance report covering Amgen Inc. (AMGN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

AMGN Bull vs. Bear Conversation Board — What's Your Call at $466.01?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON AMGN 🐻 33% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐂 BULLISH 🎯 Target: $543.66 (+18.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is AMGN (B- • RQD 71/100) a Buy at $460.73?

Welcome to the AMGN (Amgen Inc.) Roar Pit. Current RQD Composite is 71/100 (Roarable Buy — Sound Institutional Accumulation) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to capital efficiency (14.5% ROIC), while bears focus on valuation multiple compression (32.3x trailing P/E). Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RI RiskArb_Desk Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $368.58 (-20.0%)

Spot @ $460.73

Pump the brakes on AMGN — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on AMGN, but look at what you are paying: 32.3x trailing P/E with 67.2% gross margins. Unless Amgen Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH 🎯 Target: $589.73 (+28.0%)

Spot @ $460.73

AMGN cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on AMGN, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $460.73 (52-wk range $292.12 - $475.65), any beat on forward guidance forces shorts and underweight funds to chase.